Disease surveillance

The longitudinal nature of our data enables us to follow patients and variables over time. The data provide insight in the long-term effects of medication use on health outcomes and can be used to examine the effect of policy change on disease outcomes, drug utilisation or prescribing habits. For more information on disease-specific data, click here.

For example, the PHARMO Database Network was used to identify exacerbations in patients with COPD. In previous studies exacerbations were identified in a hospital setting. However, many exacerbations appear to be handled in primary care. This results in an underestimation of the exacerbation rate. In the PHARMO Database Network, more than 70% of all exacerbations were diagnosed and treated at the GP. Excluding either the hospital or the GP as valuable data source for the detection would thus underestimate the true exacerbation rate in COPD patients1. Click here for more information on our respiratory data.

1 Velthove KJ, Souverein PC, van Solinge WW, et al. Measuring exacerbations in obstructive lung disease. Pharmacoepidemiol Drug Saf, 2010; 19: 367-374